WY-14643 (Pirinixic Acid)

Catalog No.S8029 Synonyms: NSC 310038

For research use only.

WY 14643 (Pirinixic Acid, NSC 310038) is a potent peroxisome proliferator and activator of PPARα with EC50 of 1.5 μM.

WY-14643 (Pirinixic Acid) Chemical Structure

CAS No. 50892-23-4

Selleck's WY-14643 (Pirinixic Acid) has been cited by 13 publications

Purity & Quality Control

Choose Selective PPAR Inhibitors

Other PPAR Products

Biological Activity

Description WY 14643 (Pirinixic Acid, NSC 310038) is a potent peroxisome proliferator and activator of PPARα with EC50 of 1.5 μM.
PPARα [1]
1.5 μM(EC50)
In vitro

WY 14643 (10 μM) almost completely inhibits interleukin-1-induced production of interleukin-6 and prostaglandin and expression of cyclooxygenase-2 in aortic smooth-muscle cells, through repression of NF-κB signaling. [2] WY14643 (250 μM) reduces VCAM-1 expression levels significantly, to 52 % of TNF-α-stimulated human endothelial cells. Pretreatment of endothelial cells with WY 14643 (10 μM) before TNF-α stimulation reduces U937 cell adhesion by 50%. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep G2 cells NYPtOGg5TnWwY4Tpc44h[XO|YYm= NIjORlNC\2:waYP0JIFkfGm4aYT5JIF1KG2xdYPlJHBRSVKjbIDoZUBtcWejbnSgZolv\GmwZzDkc41icW5iZYjwdoV{e2WmIHnuJIh2dWGwIFjldEBIOiClZXzsd{Bkdy22cnHud4Zm[3SnZDD3bZRpKEejbEStSGJFKGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlA1KM7:TR?= NXW3RmM{OTlyNUO3O|Y>
MCF7 cells NH3QfmNHfW6ldHnvckBie3OjeR?= Mn20RYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDQVGFT[WyyaHGg[ZhxemW|c3XkJIlvKE2FRkegZ4VtdHNiY3:teJJidnOoZXP0[YQhS1CWSTDEVlEufHmyZTDSSUBi\nSncjC2JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE42PDJizszN NHniZmEzPDl|NkKzNi=>
U2OS cells NGXZeYJHfW6ldHnvckBie3OjeR?= MWTB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGDQRXJidHCqYTDpckBWOk:VIHPlcIx{KGK7IITyZY5{[WO2aY\heIlwdiCjc4PhfUwhTUN3ME2xNkDPxE1? Moq0NVg{Ojl5NUG=
HEK293 cells MmrtSpVv[3Srb36gZZN{[Xl? M4G2PGFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gVHBCWmGucHjhJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZ491emGwc3\lZ5Rm\CC5aYToJHBRWkW6ND3UT{1tfWNiYYPz[ZN{\WRiYYOgZYN1cX[jdHnvckBw\iCudXPp[oVz[XOnIHHjeIl3cXS7IH3lZZN2emWmIHHmeIVzKDR6IHjyd{BjgSC2cnHud4FkfGm4YYTpc44h[XO|YYmsJGVEPTB;MkOuN|Mh|ryP NVXPdIhnOjN{NkW4OFQ>
COS7 cells MmHnSpVv[3Srb36gZZN{[Xl? MWrBZ5RqfmG2aX;uJI9nKGi3bXHuJHBRSVKjbIDoZUBtcWejbnSgZolv\GmwZzDkc41icW5iZYjwdoV{e2WmIHnuJGNQWzdiY3XscJMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyPUO2MlMh|ryP MWeyOVA{PzlzNB?=
EAhy926 cells  NGnac3BHfW6ldHnvckBie3OjeR?= MYexNEB2VQ>? NW[4Tld[OTJiaB?= M2iz[mlvcGmkaYTpc44hd2ZidIXi[UBnd3KvYYTpc44hcW5iaIXtZY4hTUGqeUmyOkBk\WyuczDheEAyOCC3TTDwdoUucW6ldXLheIVlKG[xcjCxNkBpenNibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KHCqYYPlMYNwdnS{YYP0JI1q[3Kxc3PvdJk> NGHvfHEyQTB|NkW5OC=>
mouse NIH3T3 cells NVf4eXBsTnWwY4Tpc44h[XO|YYm= MW[wMlEuOTBizszN NFfRbo1VemGwc3HjeIl3[XSrb36gc4YhdW:3c3WgdoVkd22kaX7hcpQhWFCDUnHsdIhiKGW6cILld5Nm\CCrbjDtc5V{\SCQSVizWFMh[2WubIOgZZQhOC5zIIXNJJRwKDFyIIXNJIJ6KFCSUlWgZYN1cX[jdHnvckBj[XOnZDDkeYFtKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;s MkOzNVkzOzd{OEO=
HepaR cells MlfuSpVv[3Srb36gZZN{[Xl? MlT1NlUh|ryP MWmxJIRigQ>? NWiyfVNJSWexbnnzeEBi[3Srdnn0fUBifCCSUFHSZYxxcGFiaX6gbJVu[W5iSHXwZXIh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iSF3HR3MzKGenbnWg[ZhxemW|c3nvckBifCB{NTD1UUBqdmO3YnH0[YQh\m:{IEGg[IF6KGK7IIH1ZY51cXSjdHn2[UBRS1JibXX0bI9lKHKnbHH0bZZmKHSxIIXueJJm[XSnZDDjc451em:u MYmyOVQ6PzF|Mh?=
In vivo WY 14643 (1 mg/kg i.v. bolus) administration at 30 min before left anterior descending occlusion, causes significant reduction in infarct size of ∼44% in rats subjected to regional myocardial ischemia (25 min) and reperfusion (2 h). [4] WY 14643 (3 mg/kg) lowers basal plasma levels of glucose, triglycerides (-16% vs. untreated), and leptin (-52%), and also muscle triglyceride (-34%) and total long-chain acyl-CoAs (LCACoAs) (-41%) in high fat-fed rats. WY14643 substantially reduces visceral fat weight and total liver triglyceride content without increasing body weight gain. WY14643 enhances whole body insulin sensitivity (clamp glucose infusion rate increases 35% and glucose disposals 22%, vs. untreated). WY 14643 enhances insulin-mediated muscle glucose metabolic index (Rg') in red (47%) and white (63%) muscles as well as in white adipose tissue (90%), and reduces muscle triglyceride and LCACoA accumulation. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 64 mg/mL
(197.65 mM)
Ethanol 52 mg/mL
(160.59 mM)
Water Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O
For best results, use promptly after mixing.


* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 323.8


CAS No. 50892-23-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy WY-14643 (Pirinixic Acid) | WY-14643 (Pirinixic Acid) supplier | purchase WY-14643 (Pirinixic Acid) | WY-14643 (Pirinixic Acid) cost | WY-14643 (Pirinixic Acid) manufacturer | order WY-14643 (Pirinixic Acid) | WY-14643 (Pirinixic Acid) distributor